Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

This study is testing a combination of three drugs — carfilzomib, iberdomide, and dexamethasone — as an initial treatment for newly diagnosed multiple myeloma in patients who are candidates for a stem cell transplant. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with multiple myeloma - You are healthy enough to undergo a stem cell transplant - You have had no more than 1 cycle of prior treatment for myeloma - Your organ function (kidney, liver, heart, blood counts) meets required levels **You may NOT be eligible if...** - You have had more than 1 prior cycle of myeloma treatment - You are not a candidate for stem cell transplant - You have serious heart, kidney, or liver problems - You have active infections or uncontrolled other cancers Talk to your doctor to see if this trial is right for you.